Isis Pharmaceutical
- ISIS
- NASDAQ
- Consumer Products
- Latest 20.39
- Currency US$
- Change -0.42
- Percent Change -2.018 %
- Volume 1,415,023
- Wed May 22, 2013 4:00 PM EDT NASDAQ data delayed 15 minutes.
The Globe and Mail
- Open 20.84
- Previous Close 20.81
- High 21.48
- Low 20.25
- Bidx1 20.28
- Askx5 20.30
- 52-week High 05/03 23.03
- 52-week Low 11/08 7.555
- Beta 1.442
- Market Cap 2,066.13M
- EPS -0.43
- P/E --
- Forward P/E --
- PEG --
- Annual Dividend --
- Yield --
News
- Isis Pharmaceuticals to Present at the 2013 UBS Global Healthcare Conference
- Isis Pharmaceuticals Earns $3.5 Million from Biogen Idec
- Isis Pharmaceuticals to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
- Isis Pharmaceuticals Prices Public Offering Of Common Stock
- Isis Pharmaceuticals Announces Proposed Public Offering of Common Stock
Financials & Calendars
- Sales $122,170,000
- Earnings $-43,160,000
- Return on Equity n/a
- Cash Flow --
- Cash $107,650,000
- Current Ratio 6.14
12 months ended Mar 31, 2013.
Trailing 12 month results shown above.
All data is in U.S. dollars.
- Assets $552,960,000
- Liabilities $351,870,000
- Liabilities-to-Equity Ratio 1.75
Price Ratios
- Price to Sales 17.00
- Price to Book 10.32
- Price to Cash Flow n/a
Event Calendar
| Event | Last | Next | ||
|---|---|---|---|---|
| Earnings | May 7 | $-0.03 | Aug 5 | $-0.30 |
| Surprises | May 7 | -33.33% | n/a | n/a |
| Dividends | n/a | n/a | n/a | n/a |
| Splits | n/a | -- | n/a | n/a |
12 months ended May 22, 2013.
A look at major corporate events and financial announcements that are coming up.
Company Information
About the Company
Isis Pharmaceuticals, Inc. is a leading genomics-based drug discovery and development company that is focused on RNA. RNA is a novel target for drug discovery, and Isis has established a dominant position in RNA research. The company has integrated the expertise in molecular and cellular biology, medicinal chemistry, RNA biochemistry, bioinformatics, pharmacology and clinical development to create two exciting technologies, antisense and Ibis, a robust pipeline of drugs in development and genomics services.
Officers
- Stanley T. Crooke Chairman of the Board; Preside
- Elizabeth L. Hougen Senior Vice President; Finance
- Company Type: n/a
- Company Status: n/a
- Full-time Employees: n/a
-
Incorporation:
United States,
n/a -
Top 1000 Ranking:
Profit: n/a
Revenue: n/a
Assets: n/a
Head Office
2855 GAZELLE COURTCARLSBAD, CA
92010
Phone: 7609319200
Fax: (760)-6032700
Ideas & Discussion
Live Discussion of ISIS on StockTwits